V-Go requires only 1 insulin type. A U-100 fast-acting insulin should be used. Humalog® (insulin lispro, rDNA origin) and NovoLog® (insulin aspart, rDNA origin) have been tested by Valeritas, Inc. and found to be safe for use in the V-Go Wearable Insulin Delivery Device.
V-Go is available as a 30-day supply in 3 options—V-Go 20, V-Go 30, and V-Go 40.
Recommended to evaluate insulin dosing within 2-5 days of initiating V-Go and to ensure that patients have a plan to manage hypoglycemia and hyperglycemia. †Individual dosing needs may vary Understand the total daily dose of insulin your patient is actually taking with their current insulin regimen versus what is being prescribed. Selecting the correct V-Go option may lessen the risk of hypoglycemia (low blood sugar). It is common practice to reduce the total daily insulin dose when starting a patient on continuous subcutaneous insulin infusion therapy, and this reduction should be considered when starting a patient on V-Go. Download Now
As with any insulin therapy, titration with V-Go is critical to improving glycemic control. This V-Go blood sugar log helps patients track their blood sugar and adjust their weekly mealtime clicks. This resource is also available in Spanish.
When starting a patient on V-Go, 2 prescriptions are needed. Write 1 prescription for V-Go and another prescription for the U-100 fast-acting insulin. Two vials of insulin are required for V-Go 20, and 3 vials of insulin are required for V-Go 30 and V-Go 40.
*A U-100 fast-acting insulin should be used with V-Go. Humalog® (insulin lispro [rDNA origin] injection) and NovoLog® (insulin aspart [rDNA origin] injection) have been tested by Valeritas, Inc. and found to be safe for use in V-Go.2
†Be sure to click Humalog® or NovoLog®. Click “unstructured” and type in the Sig, Disp, and Pharmacy Notes manually. Humalog® is a registered trademark of Eli Lilly and Company. NovoLog® is a registered trademark of Novo Nordisk A/S.
References: 1. Data on file–Valeritas 2017. 2. Instructions for Patient Use. Valeritas Inc. 2018.